Mereo BioPharma (MREO) details Q2 2025 results in furnished press release

Rhea-AI Filing Summary

Mereo BioPharma Group plc furnished an update on its latest performance by announcing financial results for the second quarter ended June 30, 2025 and sharing recent corporate highlights. These details are provided in a press release dated August 12, 2025 that is attached as Exhibit 99.1.

The company is using this current report to make the press release available to investors, while specifying that the information is being furnished rather than filed for U.S. securities law purposes.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

trueFalse0001719714X000-00000000001719714us-gaap:CommonStockMember2025-08-122025-08-1200017197142025-08-122025-08-120001719714dei:AdrMember2025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

MEREO BIOPHARMA GROUP PLC

(Exact name of registrant as specified in its charter)

England and Wales		001-38452		Not Applicable
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4th Floor, One Cavendish Place,

London, W1G 0QF

United Kingdom

(Address of principal executive offices, including zip code)

+44-333-023-7300

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
American Depositary Shares, each representing five Ordinary Shares, par value £0.003 per share		MREO		The Nasdaq Stock Market LLC
Ordinary Shares, nominal value £0.003 per share*		*		The Nasdaq Stock Market LLC

*Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Mereo BioPharma Group plc announced its financial results for the second quarter ended June 30, 2025 and provided recent corporate highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description of Exhibit
99.1	Press Release, dated August 12, 2025.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	MEREO BIOPHARMA GROUP PLC
Date: August 12, 2025	By:	/s/ Christine Fox
		Name:	Christine Fox
		Title:	Chief Financial Officer

FAQ

What did Mereo BioPharma Group plc (MREO) disclose in this 8-K filing?

Mereo BioPharma furnished a press release announcing its financial results for the second quarter ended June 30, 2025, along with recent corporate highlights, using the 8-K as the vehicle to share this information with investors.

Which period do the latest Mereo BioPharma (MREO) results cover?

The results announced by Mereo BioPharma cover the second quarter ended June 30, 2025. The detailed figures and commentary are contained in the press release dated August 12, 2025 that is attached as Exhibit 99.1 to the current report.

Where can investors find the detailed Q2 2025 results for Mereo BioPharma (MREO)?

Investors can find detailed Q2 2025 results in the press release furnished as Exhibit 99.1. The 8-K states that this release, dated August 12, 2025, contains the full financial information and recent corporate highlights for the company.

Is the Mereo BioPharma (MREO) Q2 2025 press release considered filed or furnished?

The Q2 2025 press release is expressly treated as furnished, not filed, under U.S. securities laws. The company notes it is not subject to Section 18 liabilities nor automatically incorporated into other filings unless specifically referenced.

What exhibits are included with this Mereo BioPharma (MREO) 8-K?

The 8-K includes Exhibit 99.1, a press release dated August 12, 2025 containing Q2 2025 results and corporate highlights, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL version of the report for electronic reporting purposes.

Who signed the Mereo BioPharma (MREO) current report on Form 8-K?

The current report was signed on behalf of Mereo BioPharma Group plc by Christine Fox, the company’s Chief Financial Officer. Her signature confirms that the company has duly caused the report to be submitted under the Securities Exchange Act of 1934.